Advances in Biodegradable Microparticle Systems for Oral Anti-Diabetic Therapy: Focus on Plga and Metformin
DOI:
https://doi.org/10.29070/t0kp7z55Keywords:
Biodegradable microparticles, PLGA, Metformin, Oral drug delivery, Controlled releaseAbstract
Effective and patient-friendly therapy techniques are necessary to address diabetes mellitus, which remains a significant worldwide health issue. New developments in biodegradable microparticle systems for oral anti-diabetic treatment are the subject of this research. PLGA (Poly(lactic-co-glycolic acid)) metformin administration is the subject of special attention. Improving overall therapeutic results in diabetes treatment, increasing medication bioavailability, and assuring controlled release are the primary goals of the study, which aims to critically examine the function of PLGA-based microparticles.
Using only secondary data sources such as peer-reviewed journal articles, pharmaceutical reports, and regulatory papers retrieved from open-access platforms, this research takes a qualitative, review-based approach. To evaluate biodegradable delivery methods from a regulatory standpoint, we undertake a thematic and comparative examination of formulation techniques, polymer-drug interactions, pharmacokinetic advances, safety profiles, and more.
By preventing the drug's breakdown in the intestines and allowing for continuous release, the results show that PLGA microparticles greatly increase metformin bioavailability. Dosage frequency is reduced and patient compliance is improved by the controlled release method. The study also notes that PLGA is very compatible with metformin physicochemically, which means that the formulation will be stable and the therapeutic effects will be constant. Additionally, because their breakdown products are not harmful, biodegradable systems have great safety ratings. According to the results, microparticle systems based on PLGA provide a solid foundation for the oral administration of anti-diabetic medications. To facilitate commercialisation and widespread use, however, more regulatory standardisation and clinical validation are required.
Downloads
References
1. Anderson, J. M., & Shive, M. S. (2012). Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews, 64, 72–82.
2. Anderson, J. M., Rodriguez, A., & Chang, D. T. (2008). Foreign body reaction to biomaterials. Seminars in Immunology, 20(2), 86–100.
3. Bailey, C. J., & Turner, R. C. (1996). Metformin. New England Journal of Medicine, 334(9), 574–579.
4. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522.
5. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522.
6. Ensign, L. M., Cone, R., & Hanes, J. (2012). Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Advanced Drug Delivery Reviews, 64(6), 557–570.
7. Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014). Metformin: From mechanisms of action to therapies. Cell Metabolism, 20(6), 953–966.
8. Fredenberg, S., Wahlgren, M., Reslow, M., & Axelsson, A. (2011). The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. International Journal of Pharmaceutics, 415(1–2), 34–52.
9. Fredenberg, S., Wahlgren, M., Reslow, M., & Axelsson, A. (2011). The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems. International Journal of Pharmaceutics, 415(1–2), 34–52.
10. Gentile, P., Chiono, V., Carmagnola, I., & Hatton, P. V. (2014). An overview of poly(lactic-co-glycolic acid) (PLGA)-based biomaterials for bone tissue engineering. International Journal of Molecular Sciences, 15(3), 3640–3659.
11. Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., Ray, J. E., Timmins, P., & Williams, K. M. (2011). Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics, 50(2), 81–98.
12. Jain, R. A. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21(23), 2475–2490.
13. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397.
14. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397.
15. Patel, A., Cholkar, K., Mitra, A. K., & Singh, M. (2014). Advances in ocular drug delivery systems: Challenges and applications. Journal of Drug Delivery Science and Technology, 24(6), 595–606.
16. Rojas, L. B. A., & Gomes, M. B. (2013). Metformin: An old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome, 5(1), 6.
17. Shah, R. B., Tawakkul, M. A., & Khan, M. A. (2016). Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech, 9(1), 250–258.
18. Siepmann, J., & Siepmann, F. (2008). Mathematical modeling of drug delivery. International Journal of Pharmaceutics, 364(2), 328–343.
19. Singh, M., & Lillard, J. W. (2009). Nanoparticle-based targeted drug delivery. Experimental and Molecular Pathology, 86(3), 215–223.
20. Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. Pharmacy and Therapeutics, 42(12), 742–755.
21. Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. Pharmacy and Therapeutics, 42(12), 742–755.
22. Yin, Y., Chen, D., Qiao, M., Lu, Z., Hu, H., & Zhao, X. (2014). Preparation and evaluation of PLGA-based drug delivery systems for enhanced oral bioavailability. International Journal of Pharmaceutics, 478(2), 467–475.
